How much funding has Terrestrial Bio raised?

Terrestrial Bio has raised $103.9M in total funding, most recently a Series C round.

Who are Terrestrial Bio's investors?

Terrestrial Bio's investors include RA Capital Management, The Engine.

When was Terrestrial Bio founded?

Terrestrial Bio was founded in 2012.

Where is Terrestrial Bio headquartered?

Terrestrial Bio is headquartered in Woburn, United States.

What industry is Terrestrial Bio in?

Terrestrial Bio operates in Biotech, Healthcare.

Terrestrial Bio

Woburn, United States · Founded 2012 · $103.9M raised

Biotech

Healthcare

Headquarters: Woburn
Founded: 2012
Business Model: B2B
Website: terrestrialbio.com

Total Funding: $103.9M
Last Round: $50.0M Series CMar 2026
Rounds: 5

About

Terrestrial Bio (formerly Vaxess Technologies) has developed a temperature-stable microarray patch (MAP) platform that delivers biologics through the skin without needles, refrigeration, or cold-chain logistics, with a wear time of just five minutes. Its lead program is a once-weekly semaglutide patch for obesity and metabolic disease, pursued via both prescription and Rx-to-OTC pathways. In preclinical studies the patch has shown bioavailability above 80% and pharmacokinetics comparable to subcutaneous injection. The company operates a clinical-grade manufacturing facility in Woburn, Massachusetts and is building a new R&D/manufacturing site in Boston.

Summary

Terrestrial Bio is a Biotech company based in Woburn, United States, founded in 2012. It has raised $103.9M in total across 5 rounds, most recently a $50.0M Series C round in Mar 2026. Investors include RA Capital Management and The Engine.